Stephen Zaruby
Member of the Board of Directors
Biopharmaceuticals
Parvus Therapeutics
Canada
Biography
Mr. Zaruby has spent his career in the biopharmaceutical industry and he is currently the CEO of a publically-traded Canadian biotech company. Mr. Zaruby was President of Zymogenetics until it was acquired by Bristol-Myers Squibb in 2010 for $885 million. Before that, Mr. Zaruby served as Vice President, Global Head, Hospital/Surgical Business Unit of Bayer HealthCare Pharmaceuticals. Mr. Zaruby served as Director, Global Strategic Marketing of Bayer AG. Prior to that, Mr. Zaruby held various positions in sales, marketing and product development within the Bayer group of companies. Mr. Zaruby holds a B.Sc. from the University of Calgary. He has a long- standing association with the Calgary diabetic community and Stephen is also on the Board of Directors of the Juvenile Diabetes Research Foundation International, Seattle Guild.
Research Interest
Diabetes Research
